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Introduction 
 
In cancer therapy there is need for targeted treatment that kills tumour cells 
selectively while minimizing damage to healthy cells. In this regard, specific 
targeting of tumours through radiopharmaceuticals is increasingly 
considered as a promising strategy in oncology. Radiopharmaceuticals 
consist of a radionuclide coupled to a vector that specifically targets 
cancer-related molecules. The radionuclide, for example lutetium-177, will 
be used to visualize and/or kill the tumour cells through ionizing irradiation. 
 
Aptamers are small (5-15 kDa) synthetic oligonucleotides (DNA or RNA) 
that possess several advantages compared to other vectors, such as a 
relatively easy and cheap chemical synthesis allowing the introduction of 
chemical modifications, a selection possible against almost every target, a 
non-immunogenicity and a good tumour penetration. That is why aptamers 
are regarded as promising molecules for the development of 
radiopharmaceuticals. 
 
An aptamer targeting the Human Epidermal growth factor Receptor 3 
(HER3), which plays an important role in cancer development and 
progression, was chosen for the development of aptamer-based 
radiopharmaceuticals. 
SCK•CEN 
Boeretang 200 
BE-2400 Mol 
www.sckcen.be 
info@sckcen.be 
201235_MGijs 
An RNA aptamer sequence (53-mer, G = -24,77 
kcal.mole-1) targeting the HER3 receptor (Chen et al, 
PNAS (2003) 100, 9223-9231) was synthesized by 
Integrated DNA Technologies (Haasrode, Belgium).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The binding properties of this aptamer were tested on 
HER3-expressing cells (LS174T cells, ATCC) by flow 
cytometry (using the RiboGreen fluorescent dye, 
Invitrogen) and on the recombinant human HER3 
protein (R&D systems) by two electrophoretic mobility 
shift assays based on the detection of proteins (High 
Sensitivity Protein 250 kit, Bioanalyzer 2100, Agilent 
Technologies) or nucleic acids (1% agarose gel 
electrophoresis). 
   
Labelling of the aptamer with natural lutetium after 
coupling to a bifunctional chelator (1,4,7,10 tetra-aza-
cyclo-dodecane-1,4,7,10-tetraacetic acid  N-
hydroxysuccinimide ester or DOTA-NHS ester), was 
evaluated using electrospray ionization mass 
spectrometry (ESI-Q-TOF MS, Mass Spectrometry 
Laboratory, University of Liège, Belgium). 
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Evaluation of binding properties 
Flow cytometry using LS174T cells incubated 
without (negative control, left) and with anti-
HER3 aptamer (right) resulted in two different 
spectra. The cells incubated with the aptamers 
have a higher fluorescence (shift of the peak to 
the right) which suggests binding of the 
aptamer to the LS174T cells.  
 
 
  
Labelling 
Protein electrophoresis showed a shift of the 
peak (aptamer-HER3 protein complex, red, 
compared to the HER3 protein, blue) which 
corresponds to a difference in migration time. 
This difference suggests binding of the 
aptamer to the HER3 protein. 
 
 
  
Nucleic acid electrophoresis revealed a 
difference in migration distance between the 
aptamer-HER3 protein complex (lane 1) and 
the aptamer (lane 2) which also suggests 
binding of the aptamer to the HER3 protein. 
 
The ESI-Q-TOF MS spectrum of the DOTA-NHS ester-coupled aptamer (left 
spectrum) revealed a moderate yield of the coupling reaction. Two 
populations of peaks (sodium adducts) can be recognised as aptamers with 
and without DOTA-NHS ester. 
After labelling three populations of ammonium adducts are visible (right 
spectrum); aptamer with and without the DOTA-NHS ester and aptamers 
with the DOTA-NHS ester including an extra mass of 175 Da corresponding 
to the lutetium ion.  
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In this study, different techniques were evaluated to 
test the binding properties of an anti-HER3 aptamer to 
its target on cells or as pure protein. Furthermore, the 
aptamer was successfully coupled to DOTA-NHS ester 
and labelled with natural occurring lutetium. However, 
for a better yield, the coupling and labelling reactions 
need further optimization.  
 
In a next step, the natural lutetium will be replaced by 
radioactive lutetium-177, a promising beta-gamma 
emitter suitable for cancer therapy and imaging. Finally, 
preclinical evaluation of this potential therapeutic 
radiopharmaceutical will be performed in vitro and in 
vivo.  
Conclusion 
